首页> 美国卫生研究院文献>Nutrients >Vitamin D Deficiency and Effects of Vitamin D Supplementation on Disease Severity in Patients with Atopic Dermatitis: A Systematic Review and Meta-Analysis in Adults and Children
【2h】

Vitamin D Deficiency and Effects of Vitamin D Supplementation on Disease Severity in Patients with Atopic Dermatitis: A Systematic Review and Meta-Analysis in Adults and Children

机译:维生素D缺乏症和补充维生素D对特应性皮炎患者疾病严重程度的影响:成人和儿童的系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Research has investigated 25-hydroxyvitamin D (25(OH)D) levels in the Atopic Dermatitis (AD) population, as well as changes in AD severity after vitamin D (VitD) supplementation. We performed an up-to-date systematic review and meta-analysis of these findings. Electronic searches of MEDLINE, EMBASE and COCHRANE up to February 2018 were performed. Observational studies comparing 25(OH)D between AD patients and controls, as well as trials documenting baseline serum 25(OH)D levels and clinical severity by either SCORAD/EASI scores, were included. Of the 1085 articles retrieved, sixteen were included. A meta-analysis of eleven studies of AD patients vs. healthy controls (HC) found a mean difference of −14 nmol/L (95% CI −25 to −2) for all studies and −16 nmol/L (95% CI −31 to −1) for the paediatric studies alone. A meta-analysis of three VitD supplementation trials found lower SCORAD by −11 points (95% CI −13 to −9, p < 0.00001). This surpasses the Minimal Clinical Important Difference for AD of 9.0 points (by 22%). There were greater improvements in trials lasting three months and the mean weighted dose of all trials was 1500–1600 IU/daily. Overall, the AD population, especially the paediatric subset, may be at high-risk for lower serum 25(OH)D. Supplementation with around 1600 IU/daily results in a clinically meaningful AD severity reduction.
机译:研究调查了特应性皮炎(AD)人群中25-羟基维生素D(25(OH)D)的水平,以及补充维生素D(VitD)后AD严重程度的变化。我们对这些发现进行了最新的系统综述和荟萃分析。截至2018年2月,对MEDLINE,EMBASE和COCHRANE进行了电子搜索。包括观察性研究,该研究比较了AD患者和对照组之间的25(OH)D,以及通过SCORAD / EASI分数记录基线血清25(OH)D水平和临床严重性的试验。在检索到的1085篇文章中,包括了16篇。对11项AD患者与健康对照组(HC)的研究进行的荟萃分析发现,所有研究的平均差异为-14 nmol / L(95%CI -25至-2),而−16 nmol / L(95%CI) -31至-1)仅用于儿科研究。对三项VitD补充试验的荟萃分析发现,SCORAD降低了-11点(95%CI -13至-9,p <0.00001)。这超过了9.0点的最小临床重要差异(22%)。持续三个月的试验取得了更大的进步,所有试验的平均加权剂量为每天1500-1600 IU。总体而言,AD人群,尤其是儿科亚群,血清25(OH)D较低的人群可能处于高风险。每天补充约1600 IU可使临床上有意义的AD严重程度降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号